Company Announcement - Northeast Pharmaceutical announced the appointment of Ms. Li Xin as the new Chief Financial Officer, following the approval of the board's nomination committee and audit committee [1] Financial Performance - For the first half of 2025, Northeast Pharmaceutical's revenue composition is as follows: 52.0% from pharmaceutical manufacturing, 46.18% from pharmaceutical commerce, and 1.82% from other industries [1] - The current market capitalization of Northeast Pharmaceutical is 8.1 billion yuan [1]

Group 1 - The board of directors of Northeast Pharmaceutical Group Co., Ltd. held a meeting on September 6, 2025, via communication voting, following the notification sent on September 1, 2025 [1] - The meeting approved the proposal to appoint a new Chief Financial Officer, with a voting result of 11 votes in favor, 0 against, and 0 abstentions [1] - The proposal was reviewed and approved by the company's nomination committee and audit committee prior to the board meeting [1] Group 2 - The announcement includes a reference to a detailed disclosure regarding the appointment of the Chief Financial Officer, which can be found on the company's official information platform [1]

Core Viewpoint - Northeast Pharmaceutical Group Co., Ltd. has appointed Ms. Li Xin as the new Chief Financial Officer, effective from the date of the board meeting on September 6, 2025, until the next board election [1]. Group 1: Appointment Details - The appointment was made based on the company's development needs and was approved by the board after a nomination and qualification review process [1]. - Ms. Li Xin will replace Mr. Cai Yonggang, who has been acting as the CFO [1]. Group 2: Ms. Li Xin's Background - Ms. Li Xin, born in 1980, holds a bachelor's degree and has extensive experience in finance, having previously served as the head of the finance department at several companies [2]. - She currently holds the position of Chairman of the Supervisory Board at Fangda Carbon New Material Technology Co., Ltd. and has no significant relationships with the company's directors, supervisors, or major shareholders [2]. - Ms. Li Xin meets the qualifications required by relevant laws and regulations, including the Company Law and the Shenzhen Stock Exchange listing rules [2].

聘任公司财务总监的公告 证券代码：000597 证券简称：东北制药 公告编号：2025-062 东北制药集团股份有限公司关于 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 东北制药集团股份有限公司（简称"公司"）于 2025 年 9 月 6 日召开了第 十届董事会第六次会议，审议通过了《关于聘任公司财务总监的议案》。现将相 关事项公告如下： 根据公司发展需要，经公司总经理提名，公司董事会提名委员会、公司董事 会审计委员会任职资格审查并审议通过，公司董事会同意聘任李新女士为公司财 务总监（简历详见附件），任期自本次会议审议通过之日起至本届董事会换届之 日止。 李新女士财务总监任职生效以后，公司董事、总经理蔡永刚先生不再代行财 务总监职责。 特此公告。 东北制药集团股份有限公司董事会 2025 年 9 月 8 日 附件：李新女士简历 李新女士，1980 年出生，中国国籍，本科学历。曾任九江萍钢钢铁有限公司 财务部部长；北京方大炭素科技有限公司财务部部长、财务总监；辽宁方大集团 实业有限公司财务部副部长、部长；方大炭素新材料科技股份有限公司监事会主 席。 李新女士 ...

证券代码：000597 证券简称：东北制药 公告编号：2025-061 东北制药集团股份有限公司 第十届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 三、备查文件 公司第十届董事会第六次会议决议。 特此公告。 3.本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和《东北制药集团股份有限公司章程》的规定，会议形成的决议合法 有效。 二、董事会会议审议情况 会议审议并以记名投票表决方式通过以下议案： 议案：关于聘任公司财务总监的议案 具体内容详见公司于同日披露于巨潮资讯网的《东北制药集团股份有限公司 关于聘任公司财务总监的公告》（公告编号：2025-062）。 表决结果：同意 11 票，反对 0 票，弃权 0 票。 该议案已经公司董事会提名委员会、公司董事会审计委员会审议通过。 1.东北制药集团股份有限公司（以下简称"公司"）第十届董事会第六次会 议于 2025 年 9 月 1 日发出会议通知，于 2025 年 9 月 6 日以通讯表决的方式召开。 2.会议应参加董事 11 人，实际参 ...

Group 1 - The company announced a management change with the resignation of CFO Zhou Yana due to personal reasons, and General Manager Cai Yonggang will temporarily assume CFO responsibilities until a new appointment is made [2] - The board expressed gratitude for Zhou Yana's contributions and emphasized that the management change is a normal adjustment that will not impact the company's operations or financial management [2] Group 2 - Northeast Pharmaceutical is a large comprehensive pharmaceutical enterprise in China, with a diverse product matrix covering chemical raw materials and formulations, including core products like Vitamin C, anti-infection products, neurological drugs, and anti-tumor medications [3] - The company is actively optimizing its strategy by increasing investment in innovative drugs and high-value generics while expanding into international markets to maintain a stable market position [3] Group 3 - The company's financial performance in the first half of 2025 showed a decline in both revenue and net profit, with revenue at 3.853 billion yuan, down 7.58% year-on-year, and net profit at 129 million yuan, down 17.62% [4] - R&D expenses significantly increased to 83.49 million yuan, a rise of 84.09% compared to the previous year, indicating a strong commitment to innovation [4] Group 4 - The company has experienced frequent changes in key management positions over the past three years, including roles such as director, board secretary, and vice president [5] - The reasons for these changes are attributed to the need for strategic optimization and industry environment shifts, with plans to enhance the management team through a combination of internal selection and external recruitment [6]

延伸阅读： 2025年1至6月份，东北制药的营业收入构成为：医药制造业占比52.0%，医药商业占比46.18%，其他行 业占比1.82%。 长久物流:公司财务总监靳婷辞职 安孚科技:聘任刘剑波为公司财务总监 广誉远:聘任任岩为公司财务总监 每经AI快讯，东北制药（SZ 000597）9月1日晚间发布公告称，周雅娜女士因个人身体原因申请辞去公 司财务总监职务。 截至发稿，东北制药市值为82亿元。 ...

Group 1 - The financial director of Northeast Pharmaceutical Group, Ms. Zhou Yana, has resigned due to personal health reasons [1] - The resignation is effective immediately upon delivery to the board, and it will not affect the company's normal operations [1] - The board will appoint a new financial director in accordance with relevant regulations, and until then, Mr. Cai Yonggang will act in this capacity [1] Group 2 - Ms. Zhou Yana holds 120,000 shares in the company, and her shares will continue to be managed according to relevant regulations after her resignation [2] - The company expresses gratitude for Ms. Zhou Yana's diligent and faithful performance of her duties during her tenure [2]

Core Viewpoint - Northeast Pharmaceutical announced the resignation of its Chief Financial Officer, Zhou Yana, due to personal health reasons [1] Company Summary - The company's board of directors received a written resignation report from Zhou Yana [1] - Zhou Yana's resignation is attributed to personal health issues [1]

格隆汇9月1日丨东北制药(000597.SZ)公布，公司董事会于近日收到公司财务总监周雅娜女士的书面辞 职报告，周雅娜女士因个人身体原因申请辞去公司财务总监职务。 ...